Page last updated: 2024-09-05

lu 135252 and Diabetic Glomerulosclerosis

lu 135252 has been researched along with Diabetic Glomerulosclerosis in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amann, K; El-Shakmak, A; Gross, ML; Koch, A; Kuhlmann, A; Münter, K; Ritz, E; Szábó, A1
Amann, K; Gross, ML; Helmke, B; Münter, K; Parkman, A; Ritz, E; Schoof, A; Tulp, O1
Aus Dem Spring, C; Bollig, K; Dhein, S; Hochreuther, S; Hufnagel, C; Raschack, M1
Bauer, C; Hocher, B; Jacobi, J; Lun, A; Neumayer, HH; Priem, F; Raschack, M; Reinbacher, D; Schwarz, A1

Other Studies

4 other study(ies) available for lu 135252 and Diabetic Glomerulosclerosis

ArticleYear
ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Diabetologia, 2003, Volume: 46, Issue:6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Endothelin Receptor Antagonists; Hypertrophy; Kidney Glomerulus; Kidney Tubules; Male; Phenylpropionates; Pyrimidines; Rats; Rats, Sprague-Dawley

2003
Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker.
    Laboratory investigation; a journal of technical methods and pathology, 2003, Volume: 83, Issue:9

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Immunohistochemistry; Indoles; Kidney; Male; Phenylpropionates; Proliferating Cell Nuclear Antigen; Pyrimidines; Rats; RNA, Messenger; Transforming Growth Factor beta

2003
Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 293, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Blood Vessels; Body Weight; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Endothelin Receptor Antagonists; Endothelium, Vascular; Erythrocytes; Heart Rate; Indoles; Kidney Function Tests; Male; Muscle, Smooth, Vascular; Myocardium; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptor, Endothelin A

2000
Effects of endothelin receptor antagonists on the progression of diabetic nephropathy.
    Nephron, 2001, Volume: 87, Issue:2

    Topics: Animals; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Fibronectins; Kidney Glomerulus; Laminin; Phenylpropionates; Propionates; Pyrimidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B

2001